Next Article in Journal
Ag Nanoparticle–Functionalized Open-Ended Freestanding TiO2 Nanotube Arrays with a Scattering Layer for Improved Energy Conversion Efficiency in Dye-Sensitized Solar Cells
Next Article in Special Issue
Soft Interaction in Liposome Nanocarriers for Therapeutic Drug Delivery
Previous Article in Journal
Correlation between CdSe QD Synthesis, Post-Synthetic Treatment, and BHJ Hybrid Solar Cell Performance
Previous Article in Special Issue
Targeting and Photodynamic Killing of Cancer Cell by Nitrogen-Doped Titanium Dioxide Coupled with Folic Acid
Article Menu

Export Article

Open AccessFeature PaperArticle
Nanomaterials 2016, 6(6), 116; doi:10.3390/nano6060116

Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization

1
Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, 3775 University Street, Montreal, QC H3A 2B4, Canada
2
Division of Experimental Medicine, 1110 Pins Avenue, Montreal, QC H3A 1A3, Canada
3
Department of Microbiology, Immunology and Infectious Diseases, CHU St. Justine Research Center, University of Montreal, 3175 Cote-Ste-Catherine, Montréal, QC H3T 1C5, Canada
4
Division of Cardiac Surgery and Surgical Research, Royal Victoria Hospital, 1001 Boulevard Décarie, Montréal, QC H4A 3J1, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Luigi Pasqua
Received: 12 April 2016 / Revised: 31 May 2016 / Accepted: 3 June 2016 / Published: 15 June 2016
(This article belongs to the Special Issue Nanomaterials for Cancer Therapies)
View Full-Text   |   Download PDF [3898 KB, uploaded 15 June 2016]   |  

Abstract

Human serum albumin nanoparticles (HSA-NPs) are widely-used drug delivery systems with applications in various diseases, like cancer. For intravenous administration of HSA-NPs, the particle size, surface charge, drug loading and in vitro release kinetics are important parameters for consideration. This study focuses on the development of stable HSA-NPs containing the anti-cancer drug paclitaxel (PTX) via the emulsion-solvent evaporation method using a high-pressure homogenizer. The key parameters for the preparation of PTX-HSA-NPs are: the starting concentrations of HSA, PTX and the organic solvent, including the homogenization pressure and its number cycles, were optimized. Results indicate a size of 143.4 ± 0.7 nm and 170.2 ± 1.4 nm with a surface charge of −5.6 ± 0.8 mV and −17.4 ± 0.5 mV for HSA-NPs and PTX-HSA-NPs (0.5 mg/mL of PTX), respectively. The yield of the PTX-HSA-NPs was ~93% with an encapsulation efficiency of ~82%. To investigate the safety and effectiveness of the PTX-HSA-NPs, an in vitro drug release and cytotoxicity assay was performed on human breast cancer cell line (MCF-7). The PTX-HSA-NPs showed dose-dependent toxicity on cells of 52%, 39.3% and 22.6% with increasing concentrations of PTX at 8, 20.2 and 31.4 μg/mL, respectively. In summary, all parameters involved in HSA-NPs’ preparation, its anticancer efficacy and scale-up are outlined in this research article. View Full-Text
Keywords: human serum albumin; nanoparticles; paclitaxel; cancer; MCF-7 human serum albumin; nanoparticles; paclitaxel; cancer; MCF-7
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lomis, N.; Westfall, S.; Farahdel, L.; Malhotra, M.; Shum-Tim, D.; Prakash, S. Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization. Nanomaterials 2016, 6, 116.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nanomaterials EISSN 2079-4991 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top